In this case, an elderly patient with HER2-positive, pMMR gastric cancer, who initially did not respond to trastuzumab, experienced significant tumor shrinkage and prolonged PFS after the addition of a half-standard dose of pembrolizumab. The gene discussed is ERBB2; the disease is gastric cancer.